Mass drug administration with praziquantel is the mainstay of programs for the control of schistosomiasis morbidity. However, there is a growing recognition that treatment alone will not be sufficient for eventually effecting elimination and that additional measures will be required to interrupt transmission. In the absence of a safe and an effective vaccine for human schistosomiasis, the strategies to reduce infection levels will necessarily involve some interventions that affect the water-related stages of the schistosome life cycle: by reducing exposure to infectious water, by moderating availability of the intermediate snail host, or by decreasing contamination of water with egg-containing excreta. While much research on the importance of water on schistosomiasis has been performed, advances in these areas have perhaps languished with the ready availability of a cost-effective treatment. As some endemic areas near a shift to an elimination goal, a better understanding of water-based interventions that can be used alone or in concert with treatment will be needed. Reinvigoration of laboratory, field, and human behavioral aspects of this research now will ensure that the appropriate strategies are available by the time their implementation becomes necessary.Keywords: Schistosomiasis, Control, Elimination, Water, Snail, Transmission.Schistosomiasis differs from most waterborne diseases in that rather than through ingestion of contaminated water, people become infected when their skin comes into contact with fresh water bodies that contain the parasite. As a result, strategies to purify collected drinking water that may be effective against other waterborne pathogens do not necessarily prevent transmission of schistosome infection as the act of collecting water, along with bathing, washing, swimming, and certain occupations can expose individuals to infection. More than 230 million people in the world are infected with one of the three major species of schistosomes: Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium, and more than 700 million people are at risk for infection in developing countries in Africa, Asia, and South America.